{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:42:43Z","timestamp":1792442563781,"version":"4.5.0"},"reference-count":212,"publisher":"Bentham Science Publishers Ltd.","issue":"13","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the characteristics of this devastating disorder include the progressive and disabling deficits in the cognitive functions including reasoning, attention, judgment, comprehension, memory, and language.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>In this article, we have focused on the recent progress that has been achieved in the development of an effective AD vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary:<\/jats:title><jats:p>Currently, available treatment options of AD are limited to deliver short-term symptomatic relief only. A number of strategies targeting amyloid-beta (A\u03b2) have been developed in order to treat or prevent AD. In order to exert an effective immune response, an AD vaccine should contain adjuvants that can induce an effective anti-inflammatory T helper 2 (Th2) immune response. AD vaccines should also possess the immunogens which have the capacity to stimulate a protective immune response against various cytotoxic A\u03b2 conformers. The induction of an effective vaccine\u2019s immune response would necessitate the parallel delivery of immunogen to dendritic cells (DCs) and their priming to stimulate a Th2-polarized response. The aforesaid immune response is likely to mediate the generation of neutralizing antibodies against the neurotoxic A\u03b2 oligomers (A\u03b2Os) and also anti-inflammatory cytokines, thus preventing the AD-related inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Since there is an age-related decline in the immune functions, therefore vaccines are more likely to prevent AD instead of providing treatment. AD vaccines might be an effective and convenient approach to avoid the treatment-related huge expense.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568026620666200422105156","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T03:12:48Z","timestamp":1587611568000},"page":"1214-1234","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Emerging Promise of Immunotherapy for Alzheimer\u2019s Disease: A New Hope for the Development of Alzheimer\u2019s Vaccine"],"prefix":"10.2174","volume":"20","author":[{"given":"Md. Tanvir","family":"Kabir","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Brac University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Sahab","family":"Uddin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Southeast University, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijo","family":"Mathew","sequence":"additional","affiliation":[{"name":"Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankoj Kumar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Zoology, University of Dhaka, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Perveen","sequence":"additional","affiliation":[{"name":"Glocal School of Life Sciences, Glocal University, Saharanpur, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Md.","family":"Ashraf","sequence":"additional","affiliation":[{"name":"King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.82196","author":"Sahab Uddin M.","year":"2019","unstructured":"Sahab Uddin M.; Ashraf Md.; Introductory chapter, G. Alzheimer\u2019s disease\u2014the most common cause of dementia. Advances in Dementia Research 2019","journal-title":"Advances in Dementia Research"},{"key":"ref=2","author":"Ashraf G.","year":"2019","unstructured":"Ashraf G.; Md; Alexiou, A Biological, diagnostic and therapeutic advances in alzheimer\u2019s disease 2019","journal-title":"Md; Alexiou, A Biological, diagnostic and therapeutic advances in alzheimer\u2019s disease"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"Qiu C.","year":"2009","unstructured":"Qiu C.; Kivipelto M.; von Strauss E.; Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009,11(2),111-128","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","volume":"56","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Al Mamun A.; Abdel-Daim M.M.; Barreto G.E.; Ashraf G.M.; APOE and Alzheimer\u2019s disease: evidence mounts that targeting apoe4 may combat alzheimer\u2019s pathogenesis. Mol Neurobiol 2019,56(4),2450-2465","journal-title":"Mol Neurobiol"},{"key":"ref=5","author":"Kumar A.","year":"2019","unstructured":"Kumar A.; Tsao J.W.; Alzheimer Disease 2019","journal-title":"Alzheimer Disease"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1007\/s12035-018-1420-2","volume":"56","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Al Mamun A.; Kabir M.T.; Jakaria M.; Mathew B.; Barreto G.E.; Ashraf G.M.; Nootropic and anti-alzheimer\u2019s actions of medicinal plants: molecular insight into therapeutic potential to alleviate alzheimer\u2019s neuropathology. Mol Neurobiol 2019,56(7),4925-4944","journal-title":"Mol Neurobiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"McKhann G.","year":"1984","unstructured":"McKhann G.; Drachman D.; Folstein M.; Katzman R.; Price D.; Stadlan E.M.; Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s Disease. Neurology 1984,34(7),939-944","journal-title":"Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1001\/jama.1989.03430180093036","volume":"262","author":"Evans D.A.","year":"1989","unstructured":"Evans D.A.; Funkenstein H.H.; Albert M.S.; Scherr P.A.; Cook N.R.; Chown M.J.; Hebert L.E.; Hennekens C.H.; Taylor J.O.; Prevalence of Alzheimer\u2019s disease in a community population of older persons. Higher than previously reported. JAMA 1989,262(18),2551-2556","journal-title":"JAMA"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000481812","volume":"25","author":"Uddin M.S.","year":"2018","unstructured":"Uddin M.S.; Al Mamun A.; Asaduzzaman M.; Hosn F.; Abu Sufian M.; Takeda S.; Herrera-Calderon O.; Abdel-Daim M.M.; Uddin G.M.S.; Noor M.A.A.; Begum M.M.; Kabir M.T.; Zaman S.; Sarwar M.S.; Rahman M.M.; Rafe M.R.; Hossain M.F.; Hossain M.S.; Ashraful Iqbal M.; Sujan M.A.R.; Spectrum of disease and prescription pattern for outpatients with neurological disorders: an empirical pilot study in Bangladesh. Ann Neurosci 2018,25(1),25-37","journal-title":"Ann Neurosci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.4161\/hv.27882","volume":"10","author":"Davtyan H.","year":"2014","unstructured":"Davtyan H.; Bacon A.; Petrushina I.; Zagorski K.; Cribbs D.H.; Ghochikyan A.; Agadjanyan M.G.; Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines. Hum Vaccin Immunother 2014,10(5),1248-1255","journal-title":"Hum Vaccin Immunother"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.201900177","author":"Mathew B.","year":"2019","unstructured":"Mathew B.; Parambi D.G.T.; Mathew G.E.; Uddin M.S.; Inasu S.T.; Kim H.; Marathakam A.; Unnikrishnan M.K.; Carradori S.; Emerging therapeutic potentials of dual-acting MAO and ACHe inhibitors in Alzheimer\u2019s and Parkinson\u2019s diseases. Arch Pharm (Weinheim) 2019","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.25100\/cm.v47i4.2640","volume":"47","author":"Barrera-Ocampo A.","year":"2016","unstructured":"Barrera-Ocampo A.; Lopera F.; Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb Med 2016,47(4),203-212","journal-title":"Colomb Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12640-020-00185-1","author":"Al Mamun A.","year":"2020","unstructured":"Al Mamun A.; Uddin M.S.; Kabir M.T.; Khanum S.; Sarwar M.S.; Mathew B.; Rauf A.; Ahmed M.; Ashraf G.M.; Exploring the promise of targeting ubiquitin-proteasome system to combat Alzheimer\u2019s disease. Neurotox Res 2020,1-10","journal-title":"Neurotox Res"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7039138","volume":"2020","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Kabir M.T.; Jeandet P.; Mathew B.; Ashraf G.M.; Perveen A.; Bin-Jumah M.N.; Mousa S.A.; Abdel-Daim M.M.; Novel Anti-Alzheimer\u2019s therapeutic molecules targeting amyloid precursor protein processing. Oxid Med Cell Longev 2020,2020","journal-title":"Oxid Med Cell Longev"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1111\/jphp.13132","volume":"71","author":"Harilal S.","year":"2019","unstructured":"Harilal S.; Jose J.; Parambi D.G.T.; Kumar R.; Mathew G.E.; Uddin M.S.; Kim H.; Mathew B.; Advancements in nanotherapeutics for Alzheimer\u2019s disease: current perspectives. J Pharm Pharmacol 2019,71(9),1370-1383","journal-title":"J Pharm Pharmacol"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/molecules25061267","volume":"25","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Kabir M.T.; Niaz K.; Jeandet P.; Cl\u00e9ment C.; Mathew B.; Rauf A.; Rengasamy K.R.R.; Sobarzo-S\u00e1nchez E.; Ashraf G.M.; Aleya L.; Molecular insight into the therapeutic promise of flavonoids against Alzheimer\u2019s Disease. Mol 2020,25,1267","journal-title":"Mol"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13244","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Kabir M.T.; Rahman M.M.; Mathew B.; Shah M.A.; Ashraf G.M.; TV 3326 for Alzheimer\u2019s Dementia: A Novel Multimodal ChE and MAO Inhibitors to Mitigate Alzheimer\u2019s\u2010like neuropathology. J Pharm Pharmacol [ePub Ahead of Print]2020","journal-title":"J Pharm Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2019.135624","volume":"707","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Mamun A.A.; Jakaria M.; Thangapandiyan S.; Ahmad J.; Rahman M.A.; Mathew B.; Abdel-Daim M.M.; Aleya L.; Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci Total Environ 2020,707","journal-title":"Sci Total Environ"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1007\/s12035-019-01660-3","volume":"56","author":"Hossain M.F.","year":"2019","unstructured":"Hossain M.F.; Uddin M.S.; Uddin G.M.S.; Sumsuzzman D.M.; Islam M.S.; Barreto G.E.; Mathew B.; Ashraf G.M.; Melatonin in Alzheimer\u2019s Disease: a latent endogenous regulator of neurogenesis to mitigate Alzheimer\u2019s neuropathology. Mol Neurobiol 2019,56(12),8255-8276","journal-title":"Mol Neurobiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/39479","volume":"389","author":"Beyreuther K.","year":"1997","unstructured":"Beyreuther K.; Masters C.L.; Alzheimer\u2019s disease. The ins and outs of amyloid-beta. Nature 1997,389(6652),677-678","journal-title":"Nature"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"8094","DOI":"10.1002\/jcp.27588","volume":"234","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Mamun A.A.; Labu Z.K.; Hidalgo-Lanussa O.; Barreto G.E.; Ashraf G.M.; Autophagic dysfunction in Alzheimer\u2019s disease: Cellular and molecular mechanistic approaches to halt Alzheimer\u2019s pathogenesis. J Cell Physiol 2019,234(6),8094-8112","journal-title":"J Cell Physiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"18295","DOI":"10.1074\/jbc.271.31.18295","volume":"271","author":"Selkoe D.J.","year":"1996","unstructured":"Selkoe D.J.; Amyloid \u03b2-protein and the genetics of Alzheimer\u2019s disease. J Biol Chem 1996,271(31),18295-18298","journal-title":"J Biol Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/nm1067","volume":"10","author":"Bossy-Wetzel E.","year":"2004","unstructured":"Bossy-Wetzel E.; Schwarzenbacher R.; Lipton S.A.; Molecular pathways to neurodegeneration. Nat Med 2004,10(Suppl.),S2-S9","journal-title":"Nat Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00002512-200724020-00003","volume":"24","author":"Woodhouse A.","year":"2007","unstructured":"Woodhouse A.; Dickson T.C.; Vickers J.C.; Vaccination strategies for Alzheimer\u2019s disease: A new hope? Drugs Aging 2007,24(2),107-119","journal-title":"Drugs Aging"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2019.134836","volume":"700","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Kabir M.T.; Tewari D.; Mathew B.; Aleya L.; Emerging signal regulating potential of small molecule biflavonoids to combat neuropathological insults of Alzheimer\u2019s disease. Sci Total Environ 2020,700","journal-title":"Sci Total Environ"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2174\/1381612826666200107142541","volume":"26","author":"Rahman M.A.","year":"2020","unstructured":"Rahman M.A.; Rahman M.R.; Zaman T.; Uddin M.S.; Islam R.; Abdel-Daim M.M.; Rhim H.; Emerging potential of naturally occurring autophagy modulators against neurodegeneration. Curr Pharm Des 2020,26(7),772-779","journal-title":"Curr Pharm Des"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/373523a0","volume":"373","author":"Games D.","year":"1995","unstructured":"Games D.; Adams D.; Alessandrini R.; Barbour R.; Berthelette P.; Blackwell C.; Carr T.; Clemens J.; Donaldson T.; Gillespie F.; Guido T.; Hagopian S.; Johnson-Wood K.; Khan K.; Lee M.; Leibowitz P.; Lieberburg I.; Little S.; Masliah E.; McConlogue L.; Montoya-Zavala M.; Mucke L.; Paganini L.; Penniman E.; Power M.; Schenk D.; Seubert P.; Snyder B.; Soriano F.; Tan H.; Vitale J.; Wadsworth S.; Wolozin B.; Zhao J.; Alzheimer-type neuropathology in transgenic mice overexpressing V717F \u03b2-amyloid precursor protein. Nature 1995,373(6514),523-527","journal-title":"Nature"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1523\/JNEUROSCI.23-26-08989.2003","volume":"23","author":"Richards J.G.","year":"2003","unstructured":"Richards J.G.; Higgins G.A.; Ouagazzal A-M.; Ozmen L.; Kew J.N.C.; Bohrmann B.; Malherbe P.; Brockhaus M.; Loetscher H.; Czech C.; Huber G.; Bluethmann H.; Jacobsen H.; Kemp J.A.; PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003,23(26),8989-9003","journal-title":"J Neurosci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm1123","volume":"10","author":"Cheng I.H.","year":"2004","unstructured":"Cheng I.H.; Palop J.J.; Esposito L.A.; Bien-Ly N.; Yan F.; Mucke L.; Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 2004,10(11),1190-1192","journal-title":"Nat Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1111\/j.0953-816X.2004.03397.x","volume":"19","author":"Kawasumi M.","year":"2004","unstructured":"Kawasumi M.; Chiba T.; Yamada M.; Miyamae-Kaneko M.; Matsuoka M.; Nakahara J.; Tomita T.; Iwatsubo T.; Kato S.; Aiso S.; Nishimoto I.; Kouyama K.; Targeted introduction of V642I mutation in amyloid precursor protein gene causes functional abnormality resembling early stage of Alzheimer\u2019s disease in aged mice. Eur J Neurosci 2004,19(10),2826-2838","journal-title":"Eur J Neurosci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2174\/138161212799315786","volume":"18","author":"Kitazawa M.","year":"2012","unstructured":"Kitazawa M.; Medeiros R.; Laferla F.M.; Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des 2012,18(8),1131-1147","journal-title":"Curr Pharm Des"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"99-103","DOI":"10.1126\/science.274.5284.99","volume":"274","author":"Hsiao K.","year":"1996","unstructured":"Hsiao K.; Chapman P.; Nilsen S.; Eckman C.; Harigaya Y.; Younkin S.; Yang F.; Cole G.; Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice. Science (80-) 1996,274,99-103","journal-title":"Science (80-)"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0896-6273(00)80974-5","volume":"19","author":"Borchelt D.R.","year":"1997","unstructured":"Borchelt D.R.; Ratovitski T.; van Lare J.; Lee M.K.; Gonzales V.; Jenkins N.A.; Copeland N.G.; Price D.L.; Sisodia S.S.; Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997,19(4),939-945","journal-title":"Neuron"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"13287","DOI":"10.1073\/pnas.94.24.13287","volume":"94","author":"Sturchler-Pierrat C.","year":"1997","unstructured":"Sturchler-Pierrat C.; Abramowski D.; Duke M.; Wiederhold K-H.; Mistl C.; Rothacher S.; Ledermann B.; B\u00fcrki K.; Frey P.; Paganetti P.A.; Waridel C.; Calhoun M.E.; Jucker M.; Probst A.; Staufenbiel M.; Sommer B.; Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 1997,94(24),13287-13292","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nm0198-097","volume":"4","author":"Holcomb L.","year":"1998","unstructured":"Holcomb L.; Gordon M.N.; McGowan E.; Yu X.; Benkovic S.; Jantzen P.; Wright K.; Saad I.; Mueller R.; Morgan D.; Sanders S.; Zehr C.; O\u2019Campo K.; Hardy J.; Prada C.M.; Eckman C.; Younkin S.; Hsiao K.; Duff K.; Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998,4(1),97-100","journal-title":"Nat Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"Janus C.","year":"2000","unstructured":"Janus C.; Pearson J.; McLaurin J.; Mathews P.M.; Jiang Y.; Schmidt S.D.; Chishti M.A.; Horne P.; Heslin D.; French J.; Mount H.T.J.; Nixon R.A.; Mercken M.; Bergeron C.; Fraser P.E.; St George-Hyslop P.; Westaway D.; A \u03b2 peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature 2000,408(6815),979-982","journal-title":"Nature"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","volume":"20","author":"Mucke L.","year":"2000","unstructured":"Mucke L.; Masliah E.; Yu G-Q.; Mallory M.; Rockenstein E.M.; Tatsuno G.; Hu K.; Kholodenko D.; Johnson-Wood K.; McConlogue L.; High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000,20(11),4050-4058","journal-title":"J Neurosci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"21562","DOI":"10.1074\/jbc.M100710200","volume":"276","author":"Chishti M.A.","year":"2001","unstructured":"Chishti M.A.; Yang D-S.; Janus C.; Phinney A.L.; Horne P.; Pearson J.; Strome R.; Zuker N.; Loukides J.; French J.; Turner S.; Lozza G.; Grilli M.; Kunicki S.; Morissette C.; Paquette J.; Gervais F.; Bergeron C.; Fraser P.E.; Carlson G.A.; George-Hyslop P.S.; Westaway D.; Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001,276(24),21562-21570","journal-title":"J Biol Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0014-4886(03)00252-8","volume":"184","author":"Blanchard V.","year":"2003","unstructured":"Blanchard V.; Moussaoui S.; Czech C.; Touchet N.; Bonici B.; Planche M.; Canton T.; Jedidi I.; Gohin M.; Wirths O.; Bayer T.A.; Langui D.; Duyckaerts C.; Tremp G.; Pradier L.; Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP\/PS1 transgenic mice. Exp Neurol 2003,184(1),247-263","journal-title":"Exp Neurol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","volume":"41","author":"G\u00f3mez-Isla T.","year":"1997","unstructured":"G\u00f3mez-Isla T.; Hollister R.; West H.; Mui S.; Growdon J.H.; Petersen R.C.; Parisi J.E.; Hyman B.T.; Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease. Ann Neurol 1997,41(1),17-24","journal-title":"Ann Neurol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.4103\/1673-5374.274329","volume":"15","author":"Mamun A.A.","year":"2020","unstructured":"Mamun A.A.; Uddin M.S.; Mathew B.; Ashraf G.M.; Toxic tau: structural origins of tau aggregation in Alzheimer\u2019s disease. Neural Regen Res 2020,15(8),1417-1420","journal-title":"Neural Regen Res"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.410170310","volume":"17","author":"Wisniewski K.E.","year":"1985","unstructured":"Wisniewski K.E.; Wisniewski H.M.; Wen G.Y.; Occurrence of neuropathological changes and dementia of Alzheimer\u2019s disease in Down\u2019s syndrome. Ann Neurol 1985,17(3),278-282","journal-title":"Ann Neurol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.nbd.2005.05.027","volume":"20","author":"Rib\u00e9 E.M.","year":"2005","unstructured":"Rib\u00e9 E.M.; P\u00e9rez M.; Puig B.; Gich I.; Lim F.; Cuadrado M.; Sesma T.; Catena S.; S\u00e1nchez B.; Nieto M.; G\u00f3mez-Ramos P.; Mor\u00e1n M.A.; Cabodevilla F.; Samaranch L.; Ortiz L.; P\u00e9rez A.; Ferrer I.; Avila J.; G\u00f3mez-Isla T.; Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP\/tau transgenic mice. Neurobiol Dis 2005,20(3),814-822","journal-title":"Neurobiol Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/j.1447-0594.2004.00141.x","volume":"4","author":"Tabira T.","year":"2004","unstructured":"Tabira T.; Molecular Basis of Alzheimer\u2019s Disease: From Amyloid Hypothesis to Treatment in the Foreseeable Future. Geriatr Gerontol Int 2004,4,S27-S31","journal-title":"Geriatr Gerontol Int"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1523\/JNEUROSCI.1339-09.2009","volume":"29","author":"Wilcock D.M.","year":"2009","unstructured":"Wilcock D.M.; Gharkholonarehe N.; Van Nostrand W.E.; Davis J.; Vitek M.P.; Colton C.A.; Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer\u2019s disease. J Neurosci 2009,29(25),7957-7965","journal-title":"J Neurosci"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"353-356","DOI":"10.1126\/science.1072994","volume":"297","author":"Hardy J.","year":"2002","unstructured":"Hardy J.; Selkoe D.J.; The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science (80-) 2002,297,353-356","journal-title":"Science (80-)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nri1843","volume":"6","author":"Weiner H.L.","year":"2006","unstructured":"Weiner H.L.; Frenkel D.; Immunology and immunotherapy of Alzheimer\u2019s disease. Nat Rev Immunol 2006,6(5),404-416","journal-title":"Nat Rev Immunol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2174\/156720501107140815102453","volume":"11","author":"Counts S.E.","year":"2014","unstructured":"Counts S.E.; Lahiri D.K.; Overview of immunotherapy in Alzheimer\u2019s disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD. Curr Alzheimer Res 2014,11(7),623-625","journal-title":"Curr Alzheimer Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/psyg.12368","volume":"19","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Mamun A.A.; Takeda S.; Sarwar M.S.; Begum M.M.; Analyzing the chance of developing dementia among geriatric people: a cross-sectional pilot study in Bangladesh. Psychogeriatrics 2019,19(2),87-94","journal-title":"Psychogeriatrics"},{"key":"ref=50","doi-asserted-by":"publisher","DOI":"10.2174\/1386207323666200117103144","author":"Al Mamun A.","year":"2020","unstructured":"Al Mamun A.; Uddin M.S.; KDS2010: A potent highly selective and reversible MAO-B inhibitor to abate Alzheimer\u2019s Disease. Comb Chem High Throughput Screen 23. [ePub ahead of Print]2020","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1741-7015-7-7","volume":"7","author":"Rafii M.S.","year":"2009","unstructured":"Rafii M.S.; Aisen P.S.; Recent developments in Alzheimer\u2019s disease therapeutics. BMC Med 2009,7,7","journal-title":"BMC Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2174\/1389203718666170810150151","volume":"19","author":"Alexiou A.","year":"2018","unstructured":"Alexiou A.; Nizami B.; Khan F.I.; Soursou G.; Vairaktarakis C.; Chatzichronis S.; Tsiamis V.; Manztavinos V.; Yarla N.S.; Md Ashraf G.; Mitochondrial dynamics and proteins related to neurodegenerative diseases. Curr Protein Pept Sci 2018,19(9),850-857","journal-title":"Curr Protein Pept Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1007\/s12035-018-1397-x","volume":"56","author":"Alexiou A.","year":"2019","unstructured":"Alexiou A.; Soursou G.; Chatzichronis S.; Gasparatos E.; Kamal M.A.; Yarla N.S.; Perveen A.; Barreto G.E.; Ashraf G.M.; Role of GTPases in the regulation of mitochondrial dynamics in alzheimer\u2019s disease and cns-related disorders. Mol Neurobiol 2019,56(6),4530-4538","journal-title":"Mol Neurobiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","volume":"31","author":"Brody D.L.","year":"2008","unstructured":"Brody D.L.; Holtzman D.M.; Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008,31,175-193","journal-title":"Annu Rev Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(08)70170-4","volume":"7","author":"Wisniewski T.","year":"2008","unstructured":"Wisniewski T.; Konietzko U.; Amyloid-\u03b2 immunisation for Alzheimer\u2019s disease. Lancet Neurol 2008,7(9),805-811","journal-title":"Lancet Neurol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0301-0082(99)00023-4","volume":"60","author":"Vickers J.C.","year":"2000","unstructured":"Vickers J.C.; Dickson T.C.; Adlard P.A.; Saunders H.L.; King C.E.; McCormack G.; The cause of neuronal degeneration in Alzheimer\u2019s disease. Prog Neurobiol 2000,60(2),139-165","journal-title":"Prog Neurobiol"},{"key":"ref=57","first-page":"91-115","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Oxidative stress in Alzheimer\u2019s disease: molecular hallmarks of underlying vulnerability. Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease 2019,91-115","journal-title":"Biological, Diagnostic and Therapeutic Advances in Alzheimer\u2019s Disease"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lfs.2019.03.055","volume":"224","author":"Zaplatic E.","year":"2019","unstructured":"Zaplatic E.; Bule M.; Shah S.Z.A.; Uddin M.S.; Niaz K.; Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer\u2019s disease. Life Sci 2019,224,109-119","journal-title":"Life Sci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"Braak H.","year":"1991","unstructured":"Braak H.; Braak E.; Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991,82(4),239-259","journal-title":"Acta Neuropathol"},{"key":"ref=60","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2020.101046","volume":"60","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Tewari D.; Mamun A.A.; Kabir M.T.; Niaz K.; Wahed M.I.I.; Barreto G.E.; Ashraf G.M.; Circadian and sleep dysfunction in Alzheimer\u2019s disease. Ageing Res Rev 2020,60","journal-title":"Ageing Res Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fcell.2019.00197","volume":"7","author":"Uddin M.S.","year":"2019","unstructured":"Uddin M.S.; Kabir M.T.; Emerging signal regulating potential of genistein against alzheimer\u2019s disease: a promising molecule of interest. Front Cell Dev Biol 2019,7,197","journal-title":"Front Cell Dev Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/cne.903340203","volume":"334","author":"Benzing W.C.","year":"1993","unstructured":"Benzing W.C.; Ikonomovic M.D.; Brady D.R.; Mufson E.J.; Armstrong D.M.; Evidence that transmitter-containing dystrophic neurites precede paired helical filament and Alz-50 formation within senile plaques in the amygdala of nondemented elderly and patients with Alzheimer\u2019s disease. J Comp Neurol 1993,334(2),176-191","journal-title":"J Comp Neurol"},{"key":"ref=63","first-page":"871","volume":"142","author":"Masliah E.","year":"1993","unstructured":"Masliah E.; Mallory M.; Hansen L.; Alford M.; DeTeresa R.; Terry R.; An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer\u2019s disease. Am J Pathol 1993,142(3),871-882","journal-title":"Am J Pathol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0006-8993(96)00811-6","volume":"739","author":"Su J.H.","year":"1996","unstructured":"Su J.H.; Cummings B.J.; Cotman C.W.; Plaque biogenesis in brain aging and Alzheimer\u2019s disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res 1996,739(1-2),79-87","journal-title":"Brain Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/exnr.1998.7010","volume":"156","author":"Dickson T.C.","year":"1999","unstructured":"Dickson T.C.; King C.E.; McCormack G.H.; Vickers J.C.; Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer\u2019s disease. Exp Neurol 1999,156(1),100-110","journal-title":"Exp Neurol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.nbd.2004.10.001","volume":"18","author":"Dickson T.C.","year":"2005","unstructured":"Dickson T.C.; Chuckowree J.A.; Chuah M.I.; West A.K.; Vickers J.C.; \u03b1-Internexin immunoreactivity reflects variable neuronal vulnerability in Alzheimer\u2019s disease and supports the role of the \u03b2-amyloid plaques in inducing neuronal injury. Neurobiol Dis 2005,18(2),286-295","journal-title":"Neurobiol Dis"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2990.1988.tb00864.x","volume":"14","author":"Braak H.","year":"1988","unstructured":"Braak H.; Braak E.; Neuropil threads occur in dendrites of tangle-bearing nerve cells. Neuropathol Appl Neurobiol 1988,14(1),39-44","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/WNL.42.3.631","volume":"42","author":"Arriagada P.V.","year":"1992","unstructured":"Arriagada P.V.; Growdon J.H.; Hedley-Whyte E.T.; Hyman B.T.; Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology 1992,42(3 Pt 1),631-639","journal-title":"Neurology"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/00005072-199655100-00008","volume":"55","author":"Lue L.F.","year":"1996","unstructured":"Lue L.F.; Brachova L.; Civin W.H.; Rogers J.; Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer\u2019s disease neurodegeneration. J Neuropathol Exp Neurol 1996,55(10),1083-1088","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1097\/00005072-199812000-00003","volume":"57","author":"Knowles R.B.","year":"1998","unstructured":"Knowles R.B.; Gomez-Isla T.; Hyman B.T.; Abeta associated neuropil changes: correlation with neuronal loss and dementia. J Neuropathol Exp Neurol 1998,57(12),1122-1130","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358:AID-ANA12>3.0.CO;2-X","volume":"45","author":"Price J.L.","year":"1999","unstructured":"Price J.L.; Morris J.C.; Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol 1999,45(3),358-368","journal-title":"Ann Neurol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2302\/kjm.36.381","volume":"36","author":"Giacobini E.","year":"1987","unstructured":"Giacobini E.; Modulation of brain acetylcholine levels with cholinesterase inhibitors as a treatment of Alzheimer disease. Keio J Med 1987,36(4),381-391","journal-title":"Keio J Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.2174\/1381612825666191008103141","volume":"25","author":"Kabir M.T.","year":"2019","unstructured":"Kabir M.T.; Uddin M.S.; Begum M.M.; Thangapandiyan S.; Rahman M.S.; Aleya L.; Mathew B.; Ahmed M.; Barreto G.E.; Ashraf G.M.; Cholinesterase inhibitors for Alzheimer\u2019s Disease: Multitargeting strategy based on anti-alzheimer\u2019s drugs repositioning. Curr Pharm Des 2019,25(33),3519-3535","journal-title":"Curr Pharm Des"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0149-7634(05)80046-6","volume":"16","author":"Advokat C.","year":"1992","unstructured":"Advokat C.; Pellegrin A.I.; Excitatory amino acids and memory: evidence from research on Alzheimer\u2019s disease and behavioral pharmacology. Neurosci Biobehav Rev 1992,16(1),13-24","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/1381612825666191011102444","volume":"25","author":"Kabir M.T.","year":"2019","unstructured":"Kabir M.T.; Sufian M.A.; Uddin M.S.; Begum M.M.; Akhter S.; Islam A.; Mathew B.; Islam M.S.; Amran M.S.; Md Ashraf G.; NMDA receptor antagonists: repositioning of memantine as a multitargeting agent for Alzheimer\u2019s therapy. Curr Pharm Des 2019,25(33),3506-3518","journal-title":"Curr Pharm Des"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1590\/1414-431X20143434","volume":"47","author":"Alves R.P.S.","year":"2014","unstructured":"Alves R.P.S.; Yang M.J.; Batista M.T.; Ferreira L.C.S.; Alzheimer\u2019s disease: is a vaccine possible? Braz J Med Biol Res 2014,47(6),438-444","journal-title":"Braz J Med Biol Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-4933-10-18","volume":"10","author":"Moreth J.","year":"2013","unstructured":"Moreth J.; Mavoungou C.; Schindowski K.; Passive anti-amyloid immunotherapy in Alzheimer\u2019s disease: What are the most promising targets? Immun Ageing 2013,10(1),18","journal-title":"Immun Ageing"},{"key":"ref=78","doi-asserted-by":"publisher","DOI":"10.1201\/9780429242717","author":"Uddin M.S.","year":"2020","unstructured":"Uddin M.S.; Rashid M.; Advances in Neuropharmacology\u202f: Drugs and Therapeutics 2020","journal-title":"Advances in Neuropharmacology\u202f: Drugs and Therapeutics"},{"key":"ref=79","first-page":"89","volume":"38","author":"Khorassani F.","year":"2013","unstructured":"Khorassani F.; Hilas O.; Bapineuzumab, an investigational agent for Alzheimer\u2019s disease. P 2013,38(2),89-91","journal-title":"P"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.4161\/cc.8.11.8503","volume":"8","author":"Treusch S.","year":"2009","unstructured":"Treusch S.; Cyr D.M.; Lindquist S.; Amyloid deposits: protection against toxic protein species? Cell Cycle 2009,8(11),1668-1674","journal-title":"Cell Cycle"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000449482","volume":"23","author":"Uddin M.S.","year":"2016","unstructured":"Uddin M.S.; Mamun A.A.; Hossain M.S.; Akter F.; Iqbal M.A.; Asaduzzaman M.; Exploring the effect of phyllanthus emblica L. on cognitive performance, brain antioxidant markers and acetylcholinesterase activity in rats: promising natural gift for the mitigation of Alzheimer\u2019s Disease. Ann Neurosci 2016,23(4),218-229","journal-title":"Ann Neurosci"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.2174\/1567205014666170203125942","volume":"14","author":"Mantzavinos V.","year":"2017","unstructured":"Mantzavinos V.; Alexiou A.; Biomarkers for Alzheimer\u2019s disease diagnosis. Curr Alzheimer Res 2017,14(11),1149-1154","journal-title":"Curr Alzheimer Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1297.001","volume":"1019","author":"Lee H.G.","year":"2004","unstructured":"Lee H.G.; Casadesus G.; Zhu X.; Takeda A.; Perry G.; Smith M.A.; Challenging the amyloid cascade hypothesis: senile plaques and amyloid-\u03b2 as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 2004,1019,1-4","journal-title":"Ann N Y Acad Sci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"Aizenstein H.J.","year":"2008","unstructured":"Aizenstein H.J.; Nebes R.D.; Saxton J.A.; Price J.C.; Mathis C.A.; Tsopelas N.D.; Ziolko S.K.; James J.A.; Snitz B.E.; Houck P.R.; Bi W.; Cohen A.D.; Lopresti B.J.; DeKosky S.T.; Halligan E.M.; Klunk W.E.; Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008,65(11),1509-1517","journal-title":"Arch Neurol"},{"key":"ref=85","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2015.0429","volume":"371","author":"Busche M.A.","year":"2016","unstructured":"Busche M.A.; Konnerth A.; Impairments of neural circuit function in Alzheimer\u2019s disease. Philos Trans R Soc Lond B Biol Sci 2016,371(1700)","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/nn.4163","volume":"18","author":"Busche M.A.","year":"2015","unstructured":"Busche M.A.; Grienberger C.; Keskin A.D.; Song B.; Neumann U.; Staufenbiel M.; F\u00f6rstl H.; Konnerth A.; Decreased amyloid-\u03b2 and increased neuronal hyperactivity by immunotherapy in Alzheimer\u2019s models. Nat Neurosci 2015,18(12),1725-1727","journal-title":"Nat Neurosci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12974-015-0379-4","volume":"12","author":"Liu Y-H.","year":"2015","unstructured":"Liu Y-H.; Bu X-L.; Liang C-R.; Wang Y-R.; Zhang T.; Jiao S-S.; Zeng F.; Yao X-Q.; Zhou H-D.; Deng J.; Wang Y-J.; An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation 2015,12,153","journal-title":"J Neuroinflammation"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13024-017-0228-2","volume":"12","author":"Bai Y.","year":"2017","unstructured":"Bai Y.; Li M.; Zhou Y.; Ma L.; Qiao Q.; Hu W.; Li W.; Wills Z.P.; Gan W-B.; Abnormal dendritic calcium activity and synaptic depotentiation occur early in a mouse model of Alzheimer\u2019s disease. Mol Neurodegener 2017,12(1),86","journal-title":"Mol Neurodegener"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"Shankar G.M.","year":"2008","unstructured":"Shankar G.M.; Li S.; Mehta T.H.; Garcia-Munoz A.; Shepardson N.E.; Smith I.; Brett F.M.; Farrell M.A.; Rowan M.J.; Lemere C.A.; Regan C.M.; Walsh D.M.; Sabatini B.L.; Selkoe D.J.; Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med 2008,14(8),837-842","journal-title":"Nat Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"5921","DOI":"10.1021\/acs.biochem.8b00985","volume":"57","author":"Selkoe D.J.","year":"2018","unstructured":"Selkoe D.J.; Light at the end of the amyloid Tunnel. Biochemistry 2018,57(41),5921-5922","journal-title":"Biochemistry"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2217\/imt-2018-0119","volume":"11","author":"Panza F.","year":"2019","unstructured":"Panza F.; Lozupone M.; Dibello V.; Greco A.; Daniele A.; Seripa D.; Logroscino G.; Imbimbo B.P.; Are antibodies directed against amyloid-\u03b2 (A\u03b2) oligomers the last call for the A\u03b2 hypothesis of Alzheimer\u2019s disease? Immunotherapy 2019,11(1),3-6","journal-title":"Immunotherapy"},{"key":"ref=92","first-page":"255","volume":"4","author":"Budd Haeberlein S.","year":"2017","unstructured":"Budd Haeberlein S.; O\u2019Gorman J.; Chiao P.; Bussi\u00e8re T.; von Rosenstiel P.; Tian Y.; Zhu Y.; von Hehn C.; Gheuens S.; Skordos L.; Chen T.; Sandrock A.; Clinical development of aducanumab, an Anti-A\u03b2 human monoclonal antibody being investigated for the treatment of early Alzheimer\u2019s Disease. J Prev Alzheimers Dis 2017,4(4),255-263","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"Sevigny J.","year":"2016","unstructured":"Sevigny J.; Chiao P.; Bussi\u00e8re T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O\u2019Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A.; The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 2016,537(7618),50-56","journal-title":"Nature"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"Lambert M.P.","year":"1998","unstructured":"Lambert M.P.; Barlow A.K.; Chromy B.A.; Edwards C.; Freed R.; Liosatos M.; Morgan T.E.; Rozovsky I.; Trommer B.; Viola K.L.; Wals P.; Zhang C.; Finch C.E.; Krafft G.A.; Klein W.L.; Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998,95(11),6448-6453","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"S567","DOI":"10.3233\/JAD-179941","volume":"64","author":"Cline E.N.","year":"2018","unstructured":"Cline E.N.; Bicca M.A.; Viola K.L.; Klein W.L.; The amyloid-\u03b2 oligomer hypothesis: beginning of the third decade. J Alzheimers Dis 2018,64(s1),S567-S610","journal-title":"J Alzheimers Dis"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1523\/JNEUROSCI.4401-10.2011","volume":"31","author":"Dodel R.","year":"2011","unstructured":"Dodel R.; Balakrishnan K.; Keyvani K.; Deuster O.; Neff F.; Andrei-Selmer L-C.; R\u00f6skam S.; St\u00fcer C.; Al-Abed Y.; Noelker C.; Balzer-Geldsetzer M.; Oertel W.; Du Y.; Bacher M.; Naturally occurring autoantibodies against \u03b2-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer\u2019s disease. J Neurosci 2011,31(15),5847-5854","journal-title":"J Neurosci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"Selkoe D.J.","year":"2016","unstructured":"Selkoe D.J.; Hardy J.; The amyloid hypothesis of Alzheimer\u2019s disease at 25\u00a0years. EMBO Mol Med 2016,8(6),595-608","journal-title":"EMBO Mol Med"},{"key":"ref=98","doi-asserted-by":"publisher","DOI":"10.34133\/2019\/5341375","volume":"2019","author":"Marciani D.J.","year":"2019","unstructured":"Marciani D.J.; Promising results from alzheimer\u2019s disease passive immunotherapy support the development of a preventive vaccine. Research (Wash D C) 2019,2019","journal-title":"Research (Wash D C)"},{"key":"ref=99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"Sehlin D.","year":"2012","unstructured":"Sehlin D.; Englund H.; Simu B.; Karlsson M.; Ingelsson M.; Nikolajeff F.; Lannfelt L.; Pettersson F.E.; Large aggregates are the major soluble A\u03b2 species in AD brain fractionated with density gradient ultracentrifugation. PLoS One 2012,7(2)","journal-title":"PLoS One"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.20592","volume":"58","author":"Lee M.","year":"2005","unstructured":"Lee M.; Bard F.; Johnson-Wood K.; Lee C.; Hu K.; Griffith S.G.; Black R.S.; Schenk D.; Seubert P.; Abeta42 immunization in Alzheimer\u2019s disease generates Abeta N-terminal antibodies. Ann Neurol 2005,58(3),430-435","journal-title":"Ann Neurol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/j.1471-4159.2005.03407.x","volume":"95","author":"Barghorn S.","year":"2005","unstructured":"Barghorn S.; Nimmrich V.; Striebinger A.; Krantz C.; Keller P.; Janson B.; Bahr M.; Schmidt M.; Bitner R.S.; Harlan J.; Barlow E.; Ebert U.; Hillen H.; Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer\u2019s disease. J Neurochem 2005,95(3),834-847","journal-title":"J Neurochem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.cell.2016.08.005","volume":"166","author":"Briney B.","year":"2016","unstructured":"Briney B.; Sok D.; Jardine J.G.; Kulp D.W.; Skog P.; Menis S.; Jacak R.; Kalyuzhniy O.; de Val N.; Sesterhenn F.; Le K.M.; Ramos A.; Jones M.; Saye-Francisco K.L.; Blane T.R.; Spencer S.; Georgeson E.; Hu X.; Ozorowski G.; Adachi Y.; Kubitz M.; Sarkar A.; Wilson I.A.; Ward A.B.; Nemazee D.; Burton D.R.; Schief W.R.; Tailored immunogens direct affinity maturation toward hiv neutralizing antibodies. Cell 2016,166(6),1459-1470.e11","journal-title":"Cell"},{"key":"ref=103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087572","volume":"9","author":"Zolla-Pazner S.","year":"2014","unstructured":"Zolla-Pazner S.; deCamp A.; Gilbert P.B.; Williams C.; Yates N.L.; Williams W.T.; Howington R.; Fong Y.; Morris D.E.; Soderberg K.A.; Irene C.; Reichman C.; Pinter A.; Parks R.; Pitisuttithum P.; Kaewkungwal J.; Rerks-Ngarm S.; Nitayaphan S.; Andrews C.; O\u2019Connell R.J.; Yang Z.Y.; Nabel G.J.; Kim J.H.; Michael N.L.; Montefiori D.C.; Liao H-X.; Haynes B.F.; Tomaras G.D.; Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014,9(2)","journal-title":"PLoS One"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1586\/14760584.2016.1121815","volume":"15","author":"Wisniewski T.","year":"2016","unstructured":"Wisniewski T.; Drummond E.; Developing therapeutic vaccines against Alzheimer\u2019s disease. Expert Rev Vaccines 2016,15(3),401-415","journal-title":"Expert Rev Vaccines"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"140","DOI":"10.20453\/rnp.v78i3.2572","volume":"78","author":"Marciani D.J.","year":"2015","unstructured":"Marciani D.J.; Alzheimer\u2019s disease: toward the rational design of an effective vaccine. Rev Neuropsiquiatr 2015,78,140","journal-title":"Rev Neuropsiquiatr"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1080\/21645515.2016.1197456","volume":"12","author":"Yu Y-Z.","year":"2016","unstructured":"Yu Y-Z.; Xu Q.; Prophylactic immunotherapy of Alzheimer\u2019s disease using recombinant amyloid-\u03b2 B-cell epitope chimeric protein as subunit vaccine. Hum Vaccin Immunother 2016,12(11),2801-2804","journal-title":"Hum Vaccin Immunother"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.trci.2017.03.005","volume":"3","author":"Wang C.Y.","year":"2017","unstructured":"Wang C.Y.; Wang P-N.; Chiu M-J.; Finstad C.L.; Lin F.; Lynn S.; Tai Y-H.; De Fang X.; Zhao K.; Hung C-H.; Tseng Y.; Peng W-J.; Wang J.; Yu C-C.; Kuo B-S.; Frohna P.A.; UB-311, a novel UBITh amyloid \u03b2 peptide vaccine for mild\u00a0Alzheimer\u2019s\u00a0disease. Alzheimers Dement (N Y) 2017,3(2),262-272","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jneuroim.2015.08.008","volume":"287","author":"Marciani D.J.","year":"2015","unstructured":"Marciani D.J.; Alzheimer\u2019s disease vaccine development: A new strategy focusing on immune modulation. J Neuroimmunol 2015,287,54-63","journal-title":"J Neuroimmunol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13195-017-0267-5","volume":"9","author":"Wang S.W.","year":"2017","unstructured":"Wang S.W.; Liu D.Q.; Zhang L.X.; Ji M.; Zhang Y.X.; Dong Q.X.; Liu S.Y.; Xie X.X.; Liu R.T.; A vaccine with A\u03b2 oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer\u2019s disease. Alzheimers Res Ther 2017,9(1),41","journal-title":"Alzheimers Res Ther"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1002\/1873-3468.12871","volume":"591","author":"Zhang Y.X.","year":"2017","unstructured":"Zhang Y.X.; Wang S.W.; Lu S.; Zhang L.X.; Liu D.Q.; Ji M.; Wang W.Y.; Liu R.T.; A mimotope of A\u03b2 oligomers may also behave as a \u03b2-sheet inhibitor. FEBS Lett 2017,591(21),3615-3624","journal-title":"FEBS Lett"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1523\/JNEUROSCI.1189-06.2006","volume":"26","author":"Deshpande A.","year":"2006","unstructured":"Deshpande A.; Mina E.; Glabe C.; Busciglio J.; Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 2006,26(22),6011-6018","journal-title":"J Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1038\/s41598-018-21641-1","volume":"8","author":"Di Fede G.","year":"2018","unstructured":"Di Fede G.; Catania M.; Maderna E.; Ghidoni R.; Benussi L.; Tonoli E.; Giaccone G.; Moda F.; Paterlini A.; Campagnani I.; Sorrentino S.; Colombo L.; Kubis A.; Bistaffa E.; Ghetti B.; Tagliavini F.; Molecular subtypes of Alzheimer\u2019s disease. Sci Rep 2018,8(1),3269","journal-title":"Sci Rep"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"Sengupta U.","year":"2016","unstructured":"Sengupta U.; Nilson A.N.; Kayed R.; The role of amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy. EBioMedicine 2016,6,42-49","journal-title":"EBioMedicine"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1016\/S0140-6736(18)31425-9","volume":"391","author":"Burki T.","year":"2018","unstructured":"Burki T.; Alzheimer\u2019s disease research: the future of BACE inhibitors. Lancet 2018,391(10139),2486","journal-title":"Lancet"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fchem.2018.00178","volume":"6","author":"Coimbra J.R.M.","year":"2018","unstructured":"Coimbra J.R.M.; Marques D.F.F.; Baptista S.J.; Pereira C.M.F.; Moreira P.I.; Dinis T.C.P.; Santos A.E.; Salvador J.A.R.; Highlights in BACE1 Inhibitors for Alzheimer\u2019s Disease Treatment. Front Chem 2018,6,178","journal-title":"Front Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1471-4159.2001.00592.x","volume":"79","author":"Lambert M.P.","year":"2001","unstructured":"Lambert M.P.; Viola K.L.; Chromy B.A.; Chang L.; Morgan T.E.; Yu J.; Venton D.L.; Krafft G.A.; Finch C.E.; Klein W.L.; Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001,79(3),595-605","journal-title":"J Neurochem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"Bard F.","year":"2000","unstructured":"Bard F.; Cannon C.; Barbour R.; Burke R-L.; Games D.; Grajeda H.; Guido T.; Hu K.; Huang J.; Johnson-Wood K.; Khan K.; Kholodenko D.; Lee M.; Lieberburg I.; Motter R.; Nguyen M.; Soriano F.; Vasquez N.; Weiss K.; Welch B.; Seubert P.; Schenk D.; Yednock T.; Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000,6(8),916-919","journal-title":"Nat Med"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-2796.2010.02315.x","volume":"269","author":"Morgan D.","year":"2011","unstructured":"Morgan D.; Immunotherapy for Alzheimer\u2019s disease. J Intern Med 2011,269(1),54-63","journal-title":"J Intern Med"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","volume":"24","author":"Wilcock D.M.","year":"2004","unstructured":"Wilcock D.M.; Rojiani A.; Rosenthal A.; Levkowitz G.; Subbarao S.; Alamed J.; Wilson D.; Wilson N.; Freeman M.J.; Gordon M.N.; Morgan D.; Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004,24(27),6144-6151","journal-title":"J Neurosci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1096\/fj.06-6463fje","volume":"20","author":"Levites Y.","year":"2006","unstructured":"Levites Y.; Smithson L.A.; Price R.W.; Dakin R.S.; Yuan B.; Sierks M.R.; Kim J.; McGowan E.; Reed D.K.; Rosenberry T.L.; Das P.; Golde T.E.; Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer\u2019s disease mouse models. FASEB J 2006,20(14),2576-2578","journal-title":"FASEB J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"4964","DOI":"10.1523\/JNEUROSCI.4560-08.2009","volume":"29","author":"Karlnoski R.A.","year":"2009","unstructured":"Karlnoski R.A.; Rosenthal A.; Kobayashi D.; Pons J.; Alamed J.; Mercer M.; Li Q.; Gordon M.N.; Gottschall P.E.; Morgan D.; Suppression of amyloid deposition leads to long-term reductions in Alzheimer\u2019s pathologies in Tg2576 mice. J Neurosci 2009,29(15),4964-4971","journal-title":"J Neurosci"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"DeMattos R.B.","year":"2001","unstructured":"DeMattos R.B.; Bales K.R.; Cummins D.J.; Dodart J-C.; Paul S.M.; Holtzman D.M.; Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 2001,98(15),8850-8855","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"Deane R.","year":"2003","unstructured":"Deane R.; Du Yan S.; Submamaryan R.K.; LaRue B.; Jovanovic S.; Hogg E.; Welch D.; Manness L.; Lin C.; Yu J.; Zhu H.; Ghiso J.; Frangione B.; Stern A.; Schmidt A.M.; Armstrong D.L.; Arnold B.; Liliensiek B.; Nawroth P.; Hofman F.; Kindy M.; Stern D.; Zlokovic B.; RAGE mediates amyloid-\u03b2 peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003,9(7),907-913","journal-title":"Nat Med"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","volume":"94","author":"Solomon B.","year":"1997","unstructured":"Solomon B.; Koppel R.; Frankel D.; Hanan-Aharon E.; Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997,94(8),4109-4112","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","volume":"93","author":"Solomon B.","year":"1996","unstructured":"Solomon B.; Koppel R.; Hanan E.; Katzav T.; Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 1996,93(1),452-455","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"S247","DOI":"10.1016\/j.jalz.2010.05.807","volume":"6","author":"Alcantar N.A.","year":"2010","unstructured":"Alcantar N.A.; Jimenez J.; Morgan D.; Direct observation of the kinetic mechanisms for A\u00df peptide aggregation: towards elucidating alzheimer plaque dissolution. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 2010,6,S247","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"11495","DOI":"10.1523\/JNEUROSCI.3697-05.2005","volume":"25","author":"Deane R.","year":"2005","unstructured":"Deane R.; Sagare A.; Hamm K.; Parisi M.; LaRue B.; Guo H.; Wu Z.; Holtzman D.M.; Zlokovic B.V.; IgG-assisted age-dependent clearance of Alzheimer\u2019s amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005,25(50),11495-11503","journal-title":"J Neurosci"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11481-008-9114-6","volume":"3","author":"Karlnoski R.A.","year":"2008","unstructured":"Karlnoski R.A.; Rosenthal A.; Alamed J.; Ronan V.; Gordon M.N.; Gottschall P.E.; Grimm J.; Pons J.; Morgan D.; Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol 2008,3(3),187-197","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"Asuni A.A.","year":"2007","unstructured":"Asuni A.A.; Boutajangout A.; Quartermain D.; Sigurdsson E.M.; Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007,27(34),9115-9129","journal-title":"J Neurosci"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.expneurol.2010.05.010","volume":"224","author":"Boimel M.","year":"2010","unstructured":"Boimel M.; Grigoriadis N.; Lourbopoulos A.; Haber E.; Abramsky O.; Rosenmann H.; Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010,224(2),472-485","journal-title":"Exp Neurol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt278","volume":"6","author":"Kontsekova E.","year":"2014","unstructured":"Kontsekova E.; Zilka N.; Kovacech B.; Novak P.; Novak M.; First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer\u2019s disease model. Alzheimers Res Ther 2014,6(4),44","journal-title":"Alzheimers Res Ther"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"17034","DOI":"10.1038\/s41598-017-17313-1","volume":"7","author":"Rajamohamedsait H.","year":"2017","unstructured":"Rajamohamedsait H.; Rasool S.; Rajamohamedsait W.; Lin Y.; Sigurdsson E.M.; Prophylactic active tau immunization leads to sustained reduction in both tau and amyloid-\u03b2 pathologies in 3xTg mice. Sci Rep 2017,7(1),17034","journal-title":"Sci Rep"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/vaccines2030601","volume":"2","author":"Richter M.","year":"2014","unstructured":"Richter M.; Mewes A.; Fritsch M.; Kr\u00fcgel U.; Hoffmann R.; Singer D.; Doubly phosphorylated peptide vaccines to protect transgenic p301s mice against alzheimer\u2019s disease like tau aggregation. Vaccines (Basel) 2014,2(3),601-623","journal-title":"Vaccines (Basel)"},{"key":"ref=134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072301","volume":"8","author":"Theunis C.","year":"2013","unstructured":"Theunis C.; Crespo-Biel N.; Gafner V.; Pihlgren M.; L\u00f3pez-Deber M.P.; Reis P.; Hickman D.T.; Adolfsson O.; Chuard N.; Ndao D.M.; Borghgraef P.; Devijver H.; Van Leuven F.; Pfeifer A.; Muhs A.; Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One 2013,8(8)","journal-title":"PLoS One"},{"key":"ref=135","author":"Cooper H.M.","year":"2001","unstructured":"Cooper H.M.; Paterson Y.; Determination of the Specific Antibody TiterCurrent Protocols in Molecular Biology 2001","journal-title":"Determination of the Specific Antibody TiterCurrent Protocols in Molecular Biology"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"34363","DOI":"10.1038\/srep34363","volume":"6","author":"Yagi M.","year":"2016","unstructured":"Yagi M.; Palacpac N.M.Q.; Ito K.; Oishi Y.; Itagaki S.; Balikagala B.; Ntege E.H.; Yeka A.; Kanoi B.N.; Katuro O.; Shirai H.; Fukushima W.; Hirota Y.; Egwang T.G.; Horii T.; Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda. Sci Rep 2016,6,34363","journal-title":"Sci Rep"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jalz.2015.06.1884","volume":"11","author":"Agadjanyan M.G.","year":"2015","unstructured":"Agadjanyan M.G.; Petrovsky N.; Ghochikyan A.; A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer\u2019s disease. Alzheimers Dement 2015,11(10),1246-1259","journal-title":"Alzheimers Dement"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","volume":"7","author":"Jadhav S.","year":"2019","unstructured":"Jadhav S.; Avila J.; Sch\u00f6ll M.; Kovacs G.G.; K\u00f6vari E.; Skrabana R.; Evans L.D.; Kontsekova E.; Malawska B.; de Silva R.; Buee L.; Zilka N.; A walk through tau therapeutic strategies. Acta Neuropathol Commun 2019,7(1),22","journal-title":"Acta Neuropathol Commun"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","volume":"118","author":"Boutajangout A.","year":"2011","unstructured":"Boutajangout A.; Ingadottir J.; Davies P.; Sigurdsson E.M.; Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011,118(4),658-667","journal-title":"J Neurochem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2174\/156720512800492503","volume":"9","author":"Troquier L.","year":"2012","unstructured":"Troquier L.; Caillierez R.; Burnouf S.; Fernandez-Gomez F.J.; Grosjean M.E.; Zommer N.; Sergeant N.; Schraen-Maschke S.; Blum D.; Buee L.; Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012,9(4),397-405","journal-title":"Curr Alzheimer Res"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","volume":"30","author":"Boutajangout A.","year":"2010","unstructured":"Boutajangout A.; Quartermain D.; Sigurdsson E.M.; Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010,30(49),16559-16566","journal-title":"J Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026860","volume":"6","author":"Bi M.","year":"2011","unstructured":"Bi M.; Ittner A.; Ke Y.D.; G\u00f6tz J.; Ittner L.M.; Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011,6(12)","journal-title":"PLoS One"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.3233\/JAD-132237","volume":"40","author":"Ando K.","year":"2014","unstructured":"Ando K.; Kabova A.; Stygelbout V.; Leroy K.; Heraud C.; Fr\u00e9d\u00e9rick C.; Suain V.; Yilmaz Z.; Authelet M.; Dedecker R.; Potier M.C.; Duyckaerts C.; Brion J.P.; Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study. J Alzheimers Dis 2014,40(Suppl. 1),S135-S145","journal-title":"J Alzheimers Dis"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/psc.2518","volume":"19","author":"Richter M.","year":"2013","unstructured":"Richter M.; Hoffmann R.; Singer D.; T-cell epitope-dependent immune response in inbred (C57BL\/6J, SJL\/J, and C3H\/HeN) and transgenic P301S and Tg2576 mice. J Pept Sci 2013,19(7),441-451","journal-title":"J Pept Sci"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13195-018-0378-7","volume":"10","author":"Ji M.","year":"2018","unstructured":"Ji M.; Xie X.X.; Liu D.Q.; Yu X.L.; Zhang Y.; Zhang L.X.; Wang S.W.; Huang Y.R.; Liu R.T.; Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Res Ther 2018,10(1),55","journal-title":"Alzheimers Res Ther"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1016\/j.febslet.2006.05.029","volume":"580","author":"Zilka N.","year":"2006","unstructured":"Zilka N.; Filipcik P.; Koson P.; Fialova L.; Skrabana R.; Zilkova M.; Rolkova G.; Kontsekova E.; Novak M.; Truncated tau from sporadic Alzheimer\u2019s disease suffices to drive neurofibrillary degeneration in vivo. FEBS Lett 2006,580(15),3582-3588","journal-title":"FEBS Lett"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","volume":"16","author":"Novak P.","year":"2017","unstructured":"Novak P.; Schmidt R.; Kontsekova E.; Zilka N.; Kovacech B.; Skrabana R.; Vince-Kazmerova Z.; Katina S.; Fialova L.; Prcina M.; Parrak V.; Dal-Bianco P.; Brunner M.; Staffen W.; Rainer M.; Ondrus M.; Ropele S.; Smisek M.; Sivak R.; Winblad B.; Novak M.; Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 2017,16(2),123-134","journal-title":"Lancet Neurol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s10571-018-0598-1","volume":"38","author":"Brezovakova V.","year":"2018","unstructured":"Brezovakova V.; Valachova B.; Hanes J.; Novak M.; Jadhav S.; Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders. Cell Mol Neurobiol 2018,38(6),1207-1214","journal-title":"Cell Mol Neurobiol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/alzrt237","volume":"6","author":"Winblad B.","year":"2014","unstructured":"Winblad B.; Graf A.; Riviere M.E.; Andreasen N.; Ryan J.M.; Active immunotherapy options for Alzheimer\u2019s disease. Alzheimers Res Ther 2014,6(1),7","journal-title":"Alzheimers Res Ther"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/ANTI.S53336","volume":"4","author":"Du Y.","year":"2014","unstructured":"Du Y.; Gu H.; Dodel R.; Farlow M.; Advances in the development of antibody-based immunotherapy against prion disease. Antib Technol J 2014,4,45","journal-title":"Antib Technol J"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","volume":"120","author":"Glenner G.G.","year":"1984","unstructured":"Glenner G.G.; Wong C.W.; Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984,120(3),885-890","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"Goate A.","year":"1991","unstructured":"Goate A.; Chartier-Harlin M-C.; Mullan M.; Brown J.; Crawford F.; Fidani L.; Giuffra L.; Haynes A.; Irving N.; James L.; Mant R.; Newton P.; Rooke K.; Roques P.; Talbot C.; Pericak-Vance M.; Roses A.; Williamson R.; Rossor M.; Owen M.; Hardy J.; Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 1991,349(6311),704-706","journal-title":"Nature"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0197-4580(96)00001-2","volume":"17","author":"Greenberg B.D.","year":"1996","unstructured":"Greenberg B.D.; Savage M.J.; Howland D.S.; Ali S.M.; Siedlak S.L.; Perry G.; Siman R.; Scott R.W.; APP transgenesis: approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol Aging 1996,17(2),153-171","journal-title":"Neurobiol Aging"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/exnr.2001.7754","volume":"173","author":"Gordon M.N.","year":"2002","unstructured":"Gordon M.N.; Holcomb L.A.; Jantzen P.T.; DiCarlo G.; Wilcock D.; Boyett K.W.; Connor K.; Melachrino J.; O\u2019Callaghan J.P.; Morgan D.; Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002,173(2),183-195","journal-title":"Exp Neurol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"Morgan D.","year":"2000","unstructured":"Morgan D.; Diamond D.M.; Gottschall P.E.; Ugen K.E.; Dickey C.; Hardy J.; Duff K.; Jantzen P.; DiCarlo G.; Wilcock D.; Connor K.; Hatcher J.; Hope C.; Gordon M.; Arendash G.W.; A \u03b2 peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. Nature 2000,408(6815),982-985","journal-title":"Nature"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","volume":"22","author":"Kotilinek L.A.","year":"2002","unstructured":"Kotilinek L.A.; Bacskai B.; Westerman M.; Kawarabayashi T.; Younkin L.; Hyman B.T.; Younkin S.; Ashe K.H.; Reversible memory loss in a mouse transgenic model of Alzheimer\u2019s disease. J Neurosci 2002,22(15),6331-6335","journal-title":"J Neurosci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"Dodart J-C.","year":"2002","unstructured":"Dodart J-C.; Bales K.R.; Gannon K.S.; Greene S.J.; DeMattos R.B.; Mathis C.; DeLong C.A.; Wu S.; Wu X.; Holtzman D.M.; Paul S.M.; Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci 2002,5(5),452-457","journal-title":"Nat Neurosci"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/rej.2008.0677","volume":"11","author":"Lemere C.A.","year":"2008","unstructured":"Lemere C.A.; Oh J.; Stanish H.A.; Peng Y.; Pepivani I.; Fagan A.M.; Yamaguchi H.; Westmoreland S.V.; Mansfield K.G.; Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer\u2019s disease? Rejuvenation Res 2008,11(2),321-332","journal-title":"Rejuvenation Res"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0002-9440(10)63296-8","volume":"165","author":"Lemere C.A.","year":"2004","unstructured":"Lemere C.A.; Beierschmitt A.; Iglesias M.; Spooner E.T.; Bloom J.K.; Leverone J.F.; Zheng J.B.; Seabrook T.J.; Louard D.; Li D.; Selkoe D.J.; Palmour R.M.; Ervin F.R.; Alzheimer\u2019s disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004,165(1),283-297","journal-title":"Am J Pathol"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1523\/JNEUROSCI.0208-08.2008","volume":"28","author":"Head E.","year":"2008","unstructured":"Head E.; Pop V.; Vasilevko V.; Hill M.; Saing T.; Sarsoza F.; Nistor M.; Christie L-A.; Milton S.; Glabe C.; Barrett E.; Cribbs D.; A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci 2008,28(14),3555-3566","journal-title":"J Neurosci"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","volume":"24","author":"Black R.S.","year":"2010","unstructured":"Black R.S.; Sperling R.A.; Safirstein B.; Motter R.N.; Pallay A.; Nichols A.; Grundman M.; A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010,24(2),198-203","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"Salloway S.","year":"2009","unstructured":"Salloway S.; Sperling R.; Gilman S.; Fox N.C.; Blennow K.; Raskind M.; Sabbagh M.; Honig L.S.; Doody R.; van Dyck C.H.; Mulnard R.; Barakos J.; Gregg K.M.; Liu E.; Lieberburg I.; Schenk D.; Black R.; Grundman M.; A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology Bapineuzumab 201 Clinical Trial Investigators2009,73(24),2061-2070","journal-title":"Neurology"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"Risner M.E.","year":"2006","unstructured":"Risner M.E.; Saunders A.M.; Altman J.F.B.; Ormandy G.C.; Craft S.; Foley I.M.; Zvartau-Hind M.E.; Hosford D.A.; Roses A.D.; Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J Rosiglitazone in Alzheimer\u2019s Disease Study Group2006,6(4),246-254","journal-title":"Pharmacogenomics J"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1212\/WNL.50.3.669","volume":"50","author":"Farlow M.R.","year":"1998","unstructured":"Farlow M.R.; Lahiri D.K.; Poirier J.; Davignon J.; Schneider L.; Hui S.L.; Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer\u2019s disease. Neurology 1998,50(3),669-677","journal-title":"Neurology"},{"key":"ref=165","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000237","volume":"3","author":"Knight E.M.","year":"2016","unstructured":"Knight E.M.; Kim S.H.; Kottwitz J.C.; Hatami A.; Albay R.; Suzuki A.; Lublin A.; Alberini C.M.; Klein W.L.; Szabo P.; Relkin N.R.; Ehrlich M.; Glabe C.G.; Gandy S.; Steele J.W.; Effective anti-Alzheimer A\u03b2 therapy involves depletion of specific A\u03b2 oligomer subtypes. Neurol Neuroimmunol Neuroinflamm 2016,3(3)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jnc.13608","volume":"137","author":"Marciani D.J.","year":"2016","unstructured":"Marciani D.J.; A retrospective analysis of the Alzheimer\u2019s disease vaccine progress - The critical need for new development strategies. J Neurochem 2016,137(5),687-700","journal-title":"J Neurochem"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"Vellas B.","year":"2009","unstructured":"Vellas B.; Black R.; Thal L.J.; Fox N.C.; Daniels M.; McLennan G.; Tompkins C.; Leibman C.; Pomfret M.; Grundman M.; Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res AN1792 (QS-21)-251 Study Team2009,6(2),144-151","journal-title":"Curr Alzheimer Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.msard.2019.01.025","volume":"29","author":"Heidari A.R.","year":"2019","unstructured":"Heidari A.R.; Boroumand-Noughabi S.; Nosratabadi R.; Lavi Arab F.; Tabasi N.; Rastin M.; Mahmoudi M.; Acylated and deacylated quillaja saponin-21 adjuvants have opposite roles when utilized for immunization of C57BL\/6 mice model with MOG peptide. Mult Scler Relat Disord 2019,29,68-82","journal-title":"Mult Scler Relat Disord"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.drudis.2016.10.012","volume":"22","author":"Marciani D.J.","year":"2017","unstructured":"Marciani D.J.; Rejecting the Alzheimer\u2019s disease vaccine development for the wrong reasons. Drug Discov Today 2017,22(4),609-614","journal-title":"Drug Discov Today"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"Hock C.","year":"2003","unstructured":"Hock C.; Konietzko U.; Streffer J.R.; Tracy J.; Signorell A.; M\u00fcller-Tillmanns B.; Lemke U.; Henke K.; Moritz E.; Garcia E.; Wollmer M.A.; Umbricht D.; de Quervain D.J.F.; Hofmann M.; Maddalena A.; Papassotiropoulos A.; Nitsch R.M.; Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease. Neuron 2003,38(4),547-554","journal-title":"Neuron"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3233\/JAD-2010-1248","volume":"19","author":"von Bernhardi R.","year":"2010","unstructured":"von Bernhardi R.; Immunotherapy in Alzheimer\u2019s disease: where do we stand? Where should we go? J Alzheimers Dis 2010,19(2),405-421","journal-title":"J Alzheimers Dis"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"Heneka M.T.","year":"2015","unstructured":"Heneka M.T.; Carson M.J.; El Khoury J.; Landreth G.E.; Brosseron F.; Feinstein D.L.; Jacobs A.H.; Wyss-Coray T.; Vitorica J.; Ransohoff R.M.; Herrup K.; Frautschy S.A.; Finsen B.; Brown G.C.; Verkhratsky A.; Yamanaka K.; Koistinaho J.; Latz E.; Halle A.; Petzold G.C.; Town T.; Morgan D.; Shinohara M.L.; Perry V.H.; Holmes C.; Bazan N.G.; Brooks D.J.; Hunot S.; Joseph B.; Deigendesch N.; Garaschuk O.; Boddeke E.; Dinarello C.A.; Breitner J.C.; Cole G.M.; Golenbock D.T.; Kummer M.P.; Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 2015,14(4),388-405","journal-title":"Lancet Neurol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.drudis.2014.02.015","volume":"19","author":"Marciani D.J.","year":"2014","unstructured":"Marciani D.J.; New Th2 adjuvants for preventive and active immunotherapy of neurodegenerative proteinopathies. Drug Discov Today 2014,19(7),912-920","journal-title":"Drug Discov Today"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/21645515.2014.1004026","volume":"11","author":"He P.","year":"2015","unstructured":"He P.; Zou Y.; Hu Z.; Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother 2015,11(2),477-488","journal-title":"Hum Vaccin Immunother"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jprot.2017.12.021","volume":"175","author":"Kooijman S.","year":"2018","unstructured":"Kooijman S.; Brummelman J.; van Els C.A.C.M.; Marino F.; Heck A.J.R.; Mommen G.P.M.; Metz B.; Kersten G.F.A.; Pennings J.L.A.; Meiring H.D.; Novel identified aluminum hydroxide-induced pathways prove monocyte activation and pro-inflammatory preparedness. J Proteomics 2018,175,144-155","journal-title":"J Proteomics"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0079-6123(09)17506-4","volume":"175","author":"Lemere C.A.","year":"2009","unstructured":"Lemere C.A.; Developing novel immunogens for a safe and effective Alzheimer\u2019s disease vaccine. Prog Brain Res 2009,175,83-93","journal-title":"Prog Brain Res"},{"key":"ref=177","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115237","volume":"10","author":"Mandler M.","year":"2015","unstructured":"Mandler M.; Santic R.; Gruber P.; Cinar Y.; Pichler D.; Funke S.A.; Willbold D.; Schneeberger A.; Schmidt W.; Mattner F.; Tailoring the antibody response to aggregated A\u00df using novel Alzheimer-vaccines. PLoS One 2015,10(1)","journal-title":"PLoS One"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0022-1759(95)00284-7","volume":"191","author":"Boeckler C.","year":"1996","unstructured":"Boeckler C.; Frisch B.; Muller S.; Schuber F.; Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J Immunol Methods 1996,191(1),1-10","journal-title":"J Immunol Methods"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","volume":"120","author":"Delrieu J.","year":"2012","unstructured":"Delrieu J.; Ousset P.J.; Caillaud C.; Vellas B.; \u2018Clinical trials in Alzheimer\u2019s disease\u2019: immunotherapy approaches. J Neurochem 2012,120(Suppl. 1),186-193","journal-title":"J Neurochem"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2174\/1567205014666170117101537","volume":"14","author":"Hull M.","year":"2017","unstructured":"Hull M.; Sadowsky C.; Arai H.; Le Prince Leterme G.; Holstein A.; Booth K.; Peng Y.; Yoshiyama T.; Suzuki H.; Ketter N.; Liu E.; Ryan J.M.; Long-Term extensions of randomized vaccination trials of acc-001 and qs-21 in mild to moderate alzheimer\u2019s disease. Curr Alzheimer Res 2017,14(7),696-708","journal-title":"Curr Alzheimer Res"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","volume":"3","author":"Vandenberghe R.","year":"2016","unstructured":"Vandenberghe R.; Riviere M-E.; Caputo A.; Sovago J.; Maguire R.P.; Farlow M.; Marotta G.; Sanchez-Valle R.; Scheltens P.; Ryan J.M.; Graf A.; Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: A phase 2b study. Alzheimers Dement (N Y) 2016,3(1),10-22","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1016\/j.vaccine.2007.01.031","volume":"25","author":"Wang C.Y.","year":"2007","unstructured":"Wang C.Y.; Finstad C.L.; Walfield A.M.; Sia C.; Sokoll K.K.; Chang T-Y.; Fang X.D.; Hung C.H.; Hutter-Paier B.; Windisch M.; Site-specific UBITh amyloid-\u03b2 vaccine for immunotherapy of Alzheimer\u2019s disease. Vaccine 2007,25(16),3041-3052","journal-title":"Vaccine"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","volume":"10","author":"Bode C.","year":"2011","unstructured":"Bode C.; Zhao G.; Steinhagen F.; Kinjo T.; Klinman D.M.; CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011,10(4),499-511","journal-title":"Expert Rev Vaccines"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3389\/fimmu.2017.00047","volume":"8","author":"Mirotti L.","year":"2017","unstructured":"Mirotti L.; Alberca Cust\u00f3dio R.W.; Gomes E.; Rammauro F.; de Araujo E.F.; Garcia Calich V.L.; Russo M.; CpG-ODN Shapes alum adjuvant activity signaling via MyD88 and IL-10. Front Immunol 2017,8,47","journal-title":"Front Immunol"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"28912","DOI":"10.1038\/srep28912","volume":"6","author":"Davtyan H.","year":"2016","unstructured":"Davtyan H.; Zagorski K.; Rajapaksha H.; Hovakimyan A.; Davtyan A.; Petrushina I.; Kazarian K.; Cribbs D.H.; Petrovsky N.; Agadjanyan M.G.; Ghochikyan A.; Alzheimer\u2019s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A\u03b2 pathological molecules. Sci Rep 2016,6,28912","journal-title":"Sci Rep"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.neuropharm.2016.02.015","volume":"105","author":"Wang T.","year":"2016","unstructured":"Wang T.; Xie X.X.; Ji M.; Wang S.W.; Zha J.; Zhou W.W.; Yu X.L.; Wei C.; Ma S.; Xi Z.Y.; Pang G.L.; Liu R.T.; Naturally occurring autoantibodies against A\u03b2 oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer\u2019s disease than intravenous immunoglobulin. Neuropharmacology 2016,105,561-576","journal-title":"Neuropharmacology"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1038\/ncomms4898","volume":"5","author":"Gringhuis S.I.","year":"2014","unstructured":"Gringhuis S.I.; Kaptein T.M.; Wevers B.A.; Mesman A.W.; Geijtenbeek T.B.H.; Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKK\u03b5- and CYLD-dependent Bcl3 activation. Nat Commun 2014,5,3898","journal-title":"Nat Commun"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.4049\/jimmunol.168.5.2118","volume":"168","author":"Engering A.","year":"2002","unstructured":"Engering A.; Geijtenbeek T.B.H.; van Vliet S.J.; Wijers M.; van Liempt E.; Demaurex N.; Lanzavecchia A.; Fransen J.; Figdor C.G.; Piguet V.; van Kooyk Y.; The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J Immunol 2002,168(5),2118-2126","journal-title":"J Immunol"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"Holmes C.","year":"2008","unstructured":"Holmes C.; Boche D.; Wilkinson D.; Yadegarfar G.; Hopkins V.; Bayer A.; Jones R.W.; Bullock R.; Love S.; Neal J.W.; Zotova E.; Nicoll J.A.; Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008,372(9634),216-223","journal-title":"Lancet"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"Nicoll J.A.R.","year":"2006","unstructured":"Nicoll J.A.R.; Barton E.; Boche D.; Neal J.W.; Ferrer I.; Thompson P.; Vlachouli C.; Wilkinson D.; Bayer A.; Games D.; Seubert P.; Schenk D.; Holmes C.; Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol 2006,65(11),1040-1048","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1750-3639.2008.00134.x","volume":"18","author":"Boche D.","year":"2008","unstructured":"Boche D.; Nicoll J.A.R.; The role of the immune system in clearance of Abeta from the brain. Brain Pathol 2008,18(2),267-278","journal-title":"Brain Pathol"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1093\/brain\/awn261","volume":"131","author":"Boche D.","year":"2008","unstructured":"Boche D.; Zotova E.; Weller R.O.; Love S.; Neal J.W.; Pickering R.M.; Wilkinson D.; Holmes C.; Nicoll J.A.R.; Consequence of Abeta immunization on the vasculature of human Alzheimer\u2019s disease brain. Brain 2008,131(Pt 12),3299-3310","journal-title":"Brain"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"Morris J.C.","year":"2001","unstructured":"Morris J.C.; Price J.L.; Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer\u2019s disease. J Mol Neurosci 2001,17(2),101-118","journal-title":"J Mol Neurosci"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","volume":"83","author":"van Dyck C.H.","year":"2018","unstructured":"van Dyck C.H.; Anti-amyloid-\u03b2 monoclonal antibodies for alzheimer\u2019s disease: pitfalls and promise. Biol Psychiatry 2018,83(4),311-319","journal-title":"Biol Psychiatry"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bcp.2018.09.026","volume":"158","author":"Mullane K.","year":"2018","unstructured":"Mullane K.; Williams M.; Alzheimer\u2019s disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. Biochem Pharmacol 2018,158,359-375","journal-title":"Biochem Pharmacol"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrneurol.2012.118","volume":"8","author":"Liu Y-H.","year":"2012","unstructured":"Liu Y-H.; Giunta B.; Zhou H-D.; Tan J.; Wang Y-J.; Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 2012,8(8),465-469","journal-title":"Nat Rev Neurol"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1742-4658.2010.07568.x","volume":"277","author":"Sakono M.","year":"2010","unstructured":"Sakono M.; Zako T.; Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J 2010,277(6),1348-1358","journal-title":"FEBS J"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/alzrt272","volume":"6","author":"Goure W.F.","year":"2014","unstructured":"Goure W.F.; Krafft G.A.; Jerecic J.; Hefti F.; Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics. Alzheimers Res Ther 2014,6(4),42","journal-title":"Alzheimers Res Ther"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2011.07478.x","volume":"120","author":"Larson M.E.","year":"2012","unstructured":"Larson M.E.; Lesn\u00e9 S.E.; Soluble A\u03b2 oligomer production and toxicity. J Neurochem 2012,120(Suppl. 1),125-139","journal-title":"J Neurochem"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41541-018-0046-8","volume":"3","author":"Bittar A.","year":"2018","unstructured":"Bittar A.; Sengupta U.; Kayed R.; Prospects for strain-specific immunotherapy in Alzheimer\u2019s disease and tauopathies. NPJ Vaccines 2018,3,9","journal-title":"NPJ Vaccines"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.biochi.2017.07.011","volume":"140","author":"Aleksis R.","year":"2017","unstructured":"Aleksis R.; Oleskovs F.; Jaudzems K.; Pahnke J.; Biverst\u00e5l H.; Structural studies of amyloid-\u03b2 peptides: Unlocking the mechanism of aggregation and the associated toxicity. Biochimie 2017,140,176-192","journal-title":"Biochimie"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3233\/JAD-150147","volume":"47","author":"Suvorina M.Y.","year":"2015","unstructured":"Suvorina M.Y.; Selivanova O.M.; Grigorashvili E.I.; Nikulin A.D.; Marchenkov V.V.; Surin A.K.; Galzitskaya O.V.; Studies of polymorphism of amyloid-\u03b242 peptide from different suppliers. J Alzheimers Dis 2015,47(3),583-593","journal-title":"J Alzheimers Dis"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.neuron.2015.03.017","volume":"86","author":"Tycko R.","year":"2015","unstructured":"Tycko R.; Amyloid polymorphism: structural basis and neurobiological relevance. Neuron 2015,86(3),632-645","journal-title":"Neuron"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/08916934.2017.1373766","volume":"50","author":"Marciani D.J.","year":"2017","unstructured":"Marciani D.J.; Effects of immunomodulators on the response induced by vaccines against autoimmune diseases. Autoimmunity 2017,50(7),393-402","journal-title":"Autoimmunity"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13195-018-0441-4","volume":"10","author":"Rosenberg R.N.","year":"2018","unstructured":"Rosenberg R.N.; Fu M.; Lambracht-Washington D.; Active full-length DNA A\u03b2 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. Alzheimers Res Ther 2018,10(1),115","journal-title":"Alzheimers Res Ther"},{"key":"ref=206","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1189\/jlb.72.3.447","volume":"72","author":"Maletto B.","year":"2002","unstructured":"Maletto B.; R\u00f3polo A.; Mor\u00f3n V.; Pistoresi-Palencia M.C.; CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB\/c mice. J Leukoc Biol 2002,72(3),447-454","journal-title":"J Leukoc Biol"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2008.05.017","volume":"200","author":"Cao C.","year":"2008","unstructured":"Cao C.; Lin X.; Zhang C.; Wahi M.M.; Wefes I.; Arendash G.; Potter H.; Mutant amyloid-beta-sensitized dendritic cells as Alzheimer\u2019s disease vaccine. J Neuroimmunol 2008,200(1-2),1-10","journal-title":"J Neuroimmunol"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s11481-012-9371-2","volume":"7","author":"Luo Z.","year":"2012","unstructured":"Luo Z.; Li J.; Nabar N.R.; Lin X.; Bai G.; Cai J.; Zhou S-F.; Cao C.; Wang J.; Efficacy of a therapeutic vaccine using mutated \u03b2-amyloid sensitized dendritic cells in Alzheimer\u2019s mice. J Neuroimmune Pharmacol 2012,7(3),640-655","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4049\/jimmunol.167.1.442","volume":"167","author":"Okano M.","year":"2001","unstructured":"Okano M.; Satoskar A.R.; Nishizaki K.; Harn D.A.; Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens functions as adjuvant for proteins by inducing Th2-type response. J Immunol 2001,167(1),442-450","journal-title":"J Immunol"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1084\/jem.20051639","volume":"203","author":"Boscardin S.B.","year":"2006","unstructured":"Boscardin S.B.; Hafalla J.C.R.; Masilamani R.F.; Kamphorst A.O.; Zebroski H.A.; Rai U.; Morrot A.; Zavala F.; Steinman R.M.; Nussenzweig R.S.; Nussenzweig M.C.; Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006,203(3),599-606","journal-title":"J Exp Med"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.trci.2016.05.001","volume":"2","author":"Van Eldik L.J.","year":"2016","unstructured":"Van Eldik L.J.; Carrillo M.C.; Cole P.E.; Feuerbach D.; Greenberg B.D.; Hendrix J.A.; Kennedy M.; Kozauer N.; Margolin R.A.; Molinuevo J.L.; Mueller R.; Ransohoff R.M.; Wilcock D.M.; Bain L.; Bales K.; The roles of inflammation and immune mechanisms in\u00a0Alzheimer\u2019s\u00a0disease. Alzheimers Dement (N Y) 2016,2(2),99-109","journal-title":"Alzheimers Dement (N Y)"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1089\/10445490152717523","volume":"20","author":"Ugen K.E.","year":"2001","unstructured":"Ugen K.E.; Morgan D.; Alzheimer\u2019s disease: molecularly based immunotherapeutics. DNA Cell Biol 2001,20(11),677-678","journal-title":"DNA Cell Biol"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T02:43:13Z","timestamp":1666406593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181189\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":212,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,6,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200422105156","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}